Hybio Pharmaceutical Co., Ltd. (SHE:300199)
19.59
-1.47 (-6.98%)
Nov 20, 2026, 3:04 PM CST
Hybio Pharmaceutical Revenue
Hybio Pharmaceutical had revenue of 554.08M CNY in the quarter ending September 30, 2026, with 314.48% growth. This brings the company's total for the last twelve months to 1.53B, up 69.87% year-over-year. In the year 2025, Hybio Pharmaceutical had annual revenue of 966.35M with 63.73% growth. That makes Hybio Pharmaceutical the 16,534th largest company in the world by revenue and 2,996th in China.
Revenue (ttm)
1.53B
Revenue Growth
+69.87%
P/S Ratio
11.34
Revenue / Employee
1.24M
Employees
1,226
Market Cap
17.30B
Revenue by Geography
- Foreign 598.42M 61.9%
- China 367.93M 38.1%
Fiscal year ended Dec 31, 2025 See the full Hybio Pharmaceutical breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 966.35M | 376.15M | 63.73% |
| Dec 31, 2024 | 590.20M | 158.81M | 36.82% |
| Dec 31, 2023 | 431.38M | -272.94M | -38.75% |
| Jan 1, 2023 | 704.32M | -31.65M | -4.30% |
| Jan 1, 2022 | 735.97M | 14.25M | 1.97% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
Revenue RankingsHybio Pharmaceutical News
- 4 months ago - US Food and Drug Administration to review Hybio's generic GLP-1s - Reuters